Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.31 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.31 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380850 | 0.89 | ADAMTS5 (0.34) | ADAMTS5 | |
| SCHEMBL3382253 | 0.88 | ADAMTS5 (0.35) | ADAMTS5PTGS2 | |
| SCHEMBL3381612 | 0.86 | ADAMTS5 (0.33) | ADAMTS5CYP2C19GRIA2CYP2C9 | |
| SCHEMBL3379923 | 0.86 | ADAMTS5 (0.36) | ADAMTS5ALDH1A1GAAMAPT | |
| SCHEMBL1935019 | 0.82 | GAA (0.32) | GAA | |
| SCHEMBL3741118 | 0.73 | CYP2C9 (0.33) | CYP2C19CYP2C9ALDH1A1GAA | |
| SCHEMBL4030626 | 0.71 | — | — | |
| SCHEMBL3383844 | 0.71 | CYP1A2 (0.34) | ADAMTS5CYP2C19CYP2C9ALDH1A1POLB | |
| SCHEMBL3382189 | 0.71 | MEN1 (0.30) | — | |
| SCHEMBL19510500 | 0.71 | GAA (0.33) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1767528-B1 | PROCESS FOR PRODUCING 5-HYDROXY-4-THIOMETHYLPYRAZOLE COMPOUND | IHARA CHEMICAL IND CO (JP) | 2014-09-17 | — | — | EP | disclosed |
| US-7488831-B2 | Process for producing 5-hydroxy-4-thiomethylpyrazole compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-20070185334-A1 | Process for producing 5-hydroxy-4-thiomethylpyrazole compound | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1767528-A1 | PROCESS FOR PRODUCING 5-HYDROXY-4-THIOMETHYLPYRAZOLE COMPOUND | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185334-A1 | Process for producing 5-hydroxy-4-thiomethylpyrazole compound | CYP3A5, CYP4F11, GTF3C5 | ADAMTS5 1496/4885CYP2C19 28/4885GRIA2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.